Agenda - 2026 Day 3 Agenda | Pharmaceutical Compliance Congress (PCC) 2026

Key Sessions

Brook Mishler

Transforming Compliance Data into a Strategic Asset - Macro Trends and Outlier Patterns

CaseIQ

James Stansel

PhRMA (Pharmaceutical Research and Manufacturers of America) Address

PhRMA

2026 Day 3 AgendaWednesday, 29 April 2026 - ET (Eastern Time, GMT-05:00)

Showing 1 of 1 Streams

Registration

7:30am - 8:30am

Conference Registration and Continental Breakfast

Showing 3 of 3 Streams

Topic Intensive A

Topic Intensive B

Topic Intensive C

8:30am - 9:25am

Compliance Considerations for Buy & Bill Products

Variety of risks and regulatory pitfalls present in Buy and Bill products

Timothy Roberts - Global Chief Compliance Officer, Legend Biotech
Sarah Whipple - Vice President, Global Chief Compliance Officer, Apellis Pharmaceuticals

9:25am - 10:20am

COMMUNITY CONVERSATIONS Commercial Risks in Patient Support Programs

How businesses co-ordinate patient support and the relationship between commercial teams and patients
Examining different roles engaging with patients including Nurse Educators, Patient Education Liaison, and Patient Advocacy groups
Practical compliance considerations for Patient Speaker programs and Patient Ambassador Program
Examining differing approaches on transfer of value in meals, speaker honorarium etc
Internal guidelines and spend for patients, and practical questions such as if alcohol is allowed etc?

Brian Sharkey - Head of NA, Compliance and Ethics, Teva Pharmaceuticals
Chetan Shankar - Senior Director Ethics & Compliance Business Partner, Veloxis Pharmaceuticals

8:30am - 9:25am

Developments for Diagnostic Support Programs

Update DOJ and OIG on free testing
Implications for wider diagnostic testing
Anti-kickback risks
Implications of recent OIG opinion on one-time genetic test or treatment approval
What the relationships look like for diagnostics and labs

Catherine Kaucher, CCEP - Health Care Compliance Director, Johnson & Johnson
Alexis Shaw - Deputy Chief Compliance Officer, Paratek Pharmaceuticals

9:25am - 10:20am

Embedding Compliance into Organizational Culture

Understanding the DOJ and FCPA focuses for compliance culture
How do you measure the culture of compliance?
How to cultivate a culture of Compliance
How do you become ‘the voice’ of Ethics and Integrity in your organization?
Ethical conduct with compliance – understanding group think, deviance etc

Natasha Trifun - Head of Enterprise Compliance & Risk, AstraZeneca
Elizabeth Weiss - Vice President, Chief Compliance and Privacy Officer, Invivyd
Maria Villanueva - Director, Ethics and Compliance, BioTissue

8:30am - 9:25am

Navigating Data Privacy: What Compliance Professionals Need to Know

Privacy essentials for pharmaceutical companies
How do you set up privacy programs considering the varying privacy requirements and an ever-changing landscape?
As privacy considerations grow for your business, where does it sit and how do you operationalize it? Compliance vs. Legal department vs. independent privacy officer?

Erin Wagenberg - Director, Dovetail Consulting Group
Danielle Green - Senior Director, Legal & Compliance, Savara

9:25am - 10:20am

Navigating Social Media

Fundamentals of a social media policy
What are your guardrails and parameters on influencers
Social media personalities and FMV
Commercial teams on social media: where is the line when posting, liking and reposting?
How do you monitor social media? 3^rd party? Monitoring via AI?
Global risks e.g. EU /ABHI

Derek Frueh - Head of NA Compliance & Canadian General Counsel, Leo Pharma
Amy Wilson - Vice President, Chief Compliance Officer, Esperion Therapeutics

Showing 1 of 1 Streams

Networking

10:20am - 10:50am

Networking Break

Showing 1 of 1 Streams

Main Stage

10:50am - 11:40am

Transforming Compliance Data into a Strategic Asset - Macro Trends and Outlier Patterns

How are you supporting the business with your compliance data?
Shifting the perception of compliance data from a regulatory obligation to a tool for driving business performance and protecting enterprise value.
Utilizing analytics to demonstrate how compliance initiatives contribute to operational success.
How to share compliance data effectively across teams, including sales and commercial, with clear purposes and transparency.
Can compliance data help identify macro trends and areas requiring attention: connecting compliance softness and performance.

Brook Mishler - Global Director Compliance Solutions - Life Sciences, CaseIQ
Marcus Green - Vice President, Risk Analytics and Monitoring, GSK
Piyush Sharma - Chief Ethics & Compliance Officer, Alnylam Pharmaceuticals
Daryl Kreml - Head of Ethics and Compliance, Takeda Oncology
Jennifer Beaudoin - Executive Director, Head of Global Compliance Program Strategy, Assurance & Management, Vertex

11:40am - 12:10pm

KEYNOTE Key FDA Developments for Drug Advertising and Practical Compliance Take Aways

Insight into the current priorities at the FDA and their scrutiny on consumer-facing promotion.
Appetite for a sustained shift in enforcement activity.
Regulators' insight into the monitoring activities undertaken by organizations and the use of AI and social media.

12:10pm - 12:40pm

Transparency Reporting: Centers for Medicare & Medicaid Services (CMS) Open Payments Program

Developments in audits: are we going to see more scrutiny in what companies are doing? What do we need to be doing differently going forward?
Data insight: how do regulators and investigators use the data? How can companies ensure they know what is in the data and what should they expect regulators to know about their data?
New enhancements and developments on the horizon

Veronika Peleshchuk Fradlin - Director of Division of Transparency Projects (DTP), Centers for Medicare and Medicaid Services (CMS)
Amy Bedsaul - Open Payments Communications, Centers for Medicare & Medicaid Services (CMS)

12:40pm - 1:10pm

The Ripple Effects of a Shifting Payer Landscape on Compliance

Impact of recent legislative and administrative developments on drug pricing, reimbursement, and access
PBMs on shaky ground: examining the instability of Pharmacy Benefit Managers and its implications for the healthcare ecosystem
Rebates and Pharma Impact: understanding how rebate changes will primarily affect pharmaceutical companies and spill over into the medical device sector via GPOs
Implications of provider sector challenges: consequences of rising premiums and the growing physician exodus as the provider sector reaches a tipping point
Industry-wide implications: highlighting how the evolving payer and provider dynamics directly impact Life Sciences companies and their stakeholders

Meena Datta - Healthcare & Life Sciences Co-Chair, Executive Committee Member, Sidley Austin LLP

1:10pm - 1:40pm

PhRMA (Pharmaceutical Research and Manufacturers of America) Address

Impact of recent legislative and administrative developments on drug pricing, reimbursement, and access.

James Stansel - Executive Vice President, General Counsel and Corporate Secretary, PhRMA

Showing 1 of 1 Streams

Close of Day

1:40pm - 2:40pm

Close of Conference